What Does Inotiv ($NOTV) Do? Full Breakdown: Stock Outlook, Earnings, Market Cap, Peers & Headquarters

🏛️

Trading Halted Since 2026-07-17: Trading has been halted. It may resume, and prices shown reflect the last trading day. The description below is for reference only.

Company overview

What Does Inotiv ($NOTV) Do? Full Breakdown: Stock Outlook, Earnings, Market Cap, Peers & Headquarters

Updated April 23, 2026

Inotiv (NOTV) is a small- to mid-cap global CRO combining research models and nonclinical CRO services, currently in a phase of DSA order recovery and RMS restructuring.

🏢 What does Inotiv do?

Inotiv (NOTV) is a publicly traded nonclinical CRO and research animal model company headquartered in West Lafayette, Indiana, USA. Through the absorption and merger of global research model and nonclinical service firms such as Harlan and Envigo, it built its current integrated business structure, and it operates multiple laboratory animal breeding facilities and GLP nonclinical laboratories across the United States, Europe, and Israel.

The business is organized into two segments: ① Discovery and Safety Assessment (DSA), which handles target discovery, pharmacokinetics, toxicology, and safety assessment in the early stages of new drug development, and ② Research Models and Services (RMS), which supplies research animal models such as mice, rabbits, guinea pigs, and nonhuman primates, along with related feed, bioanalytics, and genetic models. In fiscal year 2025, DSA orders are showing strength, while RMS demand and pricing are fluctuating due to nonhuman primate (NHP) related issues.

💰 How does it make money?

Business Segment	Revenue Mix	Description
RMS (Research Models & Services)	Core revenue source	Revenue from supplying rodents, rabbits, nonhuman primates, and genetic models, along with breeding and genetics services. FY2025 RMS revenue approximately $82.5M	DSA (Discovery & Safety Assessment)	Growth driver	CRO services for drug discovery, toxicology, pharmacokinetics, and safety nonclinical assessment. Orders up 60% year-over-year, expanding the backlog	Genetic Models & Specialty Animals	High-value revenue	Revenue from specialty research models such as genetically modified and disease models, offering higher unit prices and margins than conventional models	Order Backlog	Revenue visibility	DSA backlog expanded to approximately $145M as of December 2025, strengthening forward revenue visibility

Fiscal year 2025 annual revenue is around $507.4M, with growth (+5.6%) in the low single-digit positive range, indicating a gradual recovery phase. Operating margin (-) remains in negative territory, but adjusted EBITDA is improving steadily as the higher-margin DSA segment sees rising orders and RMS efficiency efforts progress.

📐 Market Cap and Company Scale

Market cap stands at approximately $2.8M, roughly About 0% of Samsung Electronics' market cap. The company employs 1,945 people people.

The market cap is at the small-cap level, only about About 0% of Samsung Electronics' market cap. The company has approximately 1,945 people employees, organized as a capital-intensive infrastructure operator running laboratory animal breeding facilities and GLP laboratories.

Inotiv Outlook and Stock Price Trends

The global nonclinical CRO and research model market is a structurally growing space, driven by expansion of new drug development pipelines, increasing gene and cell therapy research, and rising demand for genetically modified and disease models. At the same time, structural headwinds persist, including the shift toward animal testing alternatives (NAMs, in silico, organoids), nonhuman primate supply and pricing issues, and tightening environmental and ethical regulations.

Compared with large CROs (Charles River, Labcorp Covance, Thermo Fisher PPD, ICON, etc.), Inotiv is smaller in scale, but it has strengths in integrated offerings that combine research models with DSA, as well as in mid-sized projects targeting academia and pharmaceutical companies. EPS ($-2.48) and ROE (-) are still in negative territory, and the debt-to-equity ratio (-), interest expense, and refinancing terms are the core measures of its financial health. The pace at which the DSA backlog converts into revenue and NHP-related disclosures will have a major impact on the short-term stock price.

⚔️ Core Competitive Strengths and Risks

Its unique business structure combining research models and nonclinical CRO services is a strength, but structural risks coexist, including high leverage, NHP supply issues, and changes in animal testing regulations.

💪 Core Competitive Strengths

Integrated Services

Provides both research models (RMS) and nonclinical CRO (DSA), enabling customers to source animal models, services, and data from a single provider

DSA Order Growth

Discovery and safety assessment orders up 60% year-over-year, rapidly expanding the order base of the higher-margin CRO segment

Global Breeding Infrastructure

Large-scale breeding facilities and GLP laboratories distributed across the U.S. and Europe, providing economies of scale and regulatory responsiveness

Genetic Model Portfolio

A portfolio of high-value specialty models, including genetically modified and disease models, securing margins and differentiation versus standard rodents

⚠️ Core Risks

NHP Supply & Pricing Risk

Volatility in nonhuman primate (NHP) supply and pricing, along with related legal and regulatory issues, directly affects RMS segment demand and margins

High-Leverage Structure

Debt accumulated from past large-scale M&A and associated interest expense pressure net income; interest rates and refinancing terms are major variables for financial health

Animal Testing Replacement Trend

Rapid development of NAMs, in silico, organoid, and organ-on-chip technologies poses a structural headwind to research model demand over the long term

Large CRO Competition

Ongoing price and scale competition with large global CROs including Charles River, Labcorp, IQVIA, Thermo Fisher (PPD), and ICON

Regulatory & Ethical Costs

Increased facility investment and operating cost burden from tightening laboratory animal management, animal welfare, and environmental regulations

🔄 Competitors and Related Stocks (Beneficiaries)

Large peers in the nonclinical CRO and research model space include Charles River Laboratories (CRL), Labcorp (LH), ICON (ICLR), IQVIA (IQV), Thermo Fisher (TMO) (PPD), Medpace (MEDP), and Fortrea (FTRE). Within research models specifically, The Jackson Laboratory (nonprofit) and Taconic Biosciences (private) are the substantive competitors. From an animal testing replacement and organoid perspective, organ-on-chip companies such as Emulate and CN Bio are indirect comparison points.

✅ Investor Checklist

Inotiv is a small- to mid-cap CRO combining research models and nonclinical CRO services. Before making any investment decision, review the following.

Checklist	What to Verify	Current Status
🧪 DSA Backlog	Track DSA order backlog, new contracts, revenue conversion pace, and shifts in concentration among key customers (Top-20 pharma)	Needs review
🐒 NHP Supply	Monitor disclosures related to nonhuman primate supply policy, pricing changes, import regulations, and their impact on RMS revenue	Needs review
💳 Debt & Interest	Review total debt, interest expense, debt/EBITDA, and refinancing terms to assess financial structure soundness	Needs review
🔁 Alternative Technology Response	Review disclosures on investment and partnerships to expand services related to NAMs, organoids, in silico, and other animal replacement technologies	Needs review

If NHP supply shocks, pricing pressure from large CROs, rapid adoption of animal testing replacement technologies, profitability pressure from rising interest expense, and shareholder dilution from additional capital raises all interact, stock price volatility could intensify.

Inotiv is a small- to mid-cap global CRO combining the two pillars of research models and nonclinical CRO services, attempting to restore profitability through DSA order recovery and RMS restructuring. While the differentiated business structure and infrastructure are clear strengths, debt, NHP, and replacement technology risks coexist, so the prudent approach is to monitor the backlog, leverage, and regulatory environment together.

Check Inotiv's real-time price, technical indicators, and peer comparison at a glance on US Stock Today's live dashboard.

1-Year Price Performance

Analyst Consensus

1.0

Sell Hold Strong Buy

52-Week Price Range

Low $0 High $3

vs. low +2.83% vs. high -97.29%